Table 1.
Demographic and clinical characteristics of study participants, stratified by seropositivity to anti-spike IgG antibodies after three vaccine doses.
| Seropositive Group (n = 59) |
Seronegative Group (n = 80) |
p Value | |
|---|---|---|---|
| S-IgG after the third vaccine dose (AU/mL, (median, IQR) |
713.40 (174.80–2398.40) | 3.25 (0.40–6.42) | <0.001 |
| S-IgG before third vaccine dose (AU/mL) (median, IQR) | 34.80 (9.10–209.35) | 2.55 (0.77–6.52) | <0.001 |
| Age (mean, SD) | 54.03 ± 13.57 | 57.86 ± 12.75 | 0.033 |
| Male gender (number, percentage) | 37 (62.7%) | 70 (58.3%) | 0.574 |
| BMI (per kg/m2) (mean, SD) | 26.39 ± 4.89 | 26.14 ± 4.44 | 0.740 |
| GFR (per ml/min/1.73m2) (mean, SD) | 69.58 ± 23.06 | 58.51 ± 23.00 | 0.003 |
| Chronic kidney disease (stage 3 and above) (number, percentage) | 7 (11.9%) | 25 (31.3%) | 0.007 |
| Time from transplantation (months) (mean, SD) | 85.22 ± 63.83 | 65.25 ± 54.10 | 0.024 |
| Immunosuppression regimen (number, percentage) |
|||
| Mycophenolate mofetil | 54 (91.5%) | 73 (92.4%) | 1.000 |
| CNI’s | 59 (100%) | 80 (100.0%) | 1.000 |
| mTOR inhibitor | 9 (15.3%) | 14 (17.5%) | 0.725 |
| Immunosuppression drug through levels (IU) (mean, SD) | 9.08 ± 2.07 | 9.80 ± 2.04 | 0.072 |
Significant p values (p < 0.05) are in bold. Abbreviations: BMI, body mass index; GFR, glomerular filtration rate; CNIs, calcineurin inhibitors; mTOR, mammalian target of rapamycin.